Skip to main content
Fig. 5 | Journal of Hematology & Oncology

Fig. 5

From: Targeting of BMI-1 with PTC-209 shows potent anti-myeloma activity and impairs the tumour microenvironment

Fig. 5

PTC-209 impairs in vitro osteoclast and tube formation. a PTC-209 significantly inhibited osteoclast formation in a dose-dependent manner verified by reduced numbers of multinucleated TRAP-positive cells at day 14 of differentiation. b The inhibitory impact on osteoclast formation was confirmed by decreased expression of cathepsin K and TRAP. c Tube formation was inhibited by PTC-209 in a dose-dependent manner. Analysis with the Angiogenesis Analyzer for ImageJ demonstrated a significant impact of PTC-209 on the total length, the number of junctions and master segments as well as the branching interval (defined as total segments length/number of branches) during the tube formation process. Images are representative for three independent experiments. ***P < 0.001, **P < 0.01 and *P < 0.05 vs DMSO control

Back to article page